23:46 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD); progressive supranuclear palsy (PSP) Patient sample and fly studies suggest PIWIL1 overexpression or inhibiting viral DNA polymerases could help treat AD, PSP and other tauopathies. In postmortem cortex and cerebellum samples from...
07:00 , Mar 19, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Deoxynucleoside triphosphate (dNTP) mimic for targeting nucleic acid polymerases

Drug platforms TECHNOLOGY: Nucleic acids A dNTP-mimicking scaffold that targets multiple nucleic acid polymerases could aid the development of therapies to treat viral infections and other diseases. The scaffold was an α-carboxy nucleoside phosphonate (α-CNP) that could...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

New England Biolabs, Roche enabling technology news

The Australian Patent Office ruled that claims in Roche's Patent No. 632,857 covering naturally-occurring DNA polymerases from Thermus bacteria species are invalid. The technology is used in polymerase chain reaction (PCR). Biolabs and Bresagen Ltd....
07:00 , May 3, 2012 |  BC Innovations  |  Tools & Techniques

Evolution not revolution

An international team has engineered enzymes capable of replicating nucleic acid polymers that are made of non-natural nucleotides.1 Despite general media reports that the findings are a breakthrough on the way to artificial life, the...
07:00 , Mar 25, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Polymerase (DNA directed)-g (POLG); POLB In vitro studies suggest that inhibiting DNA polymerases POLG and POLB...
08:00 , Mar 23, 1998 |  BC Week In Review  |  Company News

Quantum, Roche, The Perkin-Elmer Corp., Roche Molecular Systems Inc. deal

Quantum received a non-exclusive license from PKN, Roche and Roche Molecular to manufacture and sell native and recombinant Taq DNA polymerases and other thermostable enzymes for use in the Polymerase Chain Reaction (PCR) process. Quantum...
07:00 , Jul 21, 1997 |  BC Week In Review  |  Company News

Oncor, F. Hoffmann-La Roche deal

ONC's Appligene Oncor SA subsidiary (Strasbourg, France) signed a non-exclusive worldwide license agreement with Hoffmann-La Roche and its Roche Molecular Systems Inc. subsidiary (Somerville, N.J.) for polymerase chain reaction related research reagents. Appligene Oncor will...
08:00 , Nov 18, 1996 |  BC Week In Review  |  Company News

Amersham International plc, Perkin-Elmer Corp., Roche Molecular Systems deal

Perkin-Elmer's PE Applied Biosystems division and Roche Molecular Systems cross-licensed patents with Amersham that cover automated fluorescent DNA sequencing. Amersham received a non-exclusive license to patents that are exclusively licensed to Applied Biosystems. Applied...
07:00 , Jul 10, 1995 |  BC Week In Review  |  Company News

Amersham International plc other research news

Harvard University researchers published in the Proceedings of the National Academy of Sciences a method for engineering novel DNA polymerases with enhanced properties for use in DNA sequence analysis. Active site hybrids of DNA polymerases...
07:00 , Jul 10, 1995 |  BC Week In Review  |  Company News

Amersham International plc deal

Amersham's United States Biochemical Corp. subsidiary received an exclusive worldwide license from Harvard Medical School to a technology to develop DNA polymerases for use in DNA sequencing. Scientists at Harvard had previously developed Sequenase, a...